Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ASPH | Q12797 | 3/20 | 0.44 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.44 |
| ▸ | P4HTM | Q9NXG6 | 4/20 | 0.44 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1180456 | 0.84 | KDM4E (0.52) | KDM4EALDH1A1SMN1; SMN2ASPHKDM8 | |
| SCHEMBL20934640 | 0.84 | NPC1 (0.39) | KDM4EALDH1A1SMN1; SMN2GABRPGABRD | |
| SCHEMBL7083217 | 0.83 | KDM4E (0.50) | KDM4EALDH1A1SMN1; SMN2ASPHKDM8 | |
| SCHEMBL28635523 | 0.81 | KDM4E (0.48) | KDM4EALDH1A1SMN1; SMN2ASPHKDM8 | |
| SCHEMBL22978646 | 0.79 | MAPK1 (0.47) | KDM4EALDH1A1SMN1; SMN2L3MBTL1MAPK1 | |
| SCHEMBL31161438 | 0.79 | MAPK1 (0.47) | KDM4EALDH1A1SMN1; SMN2L3MBTL1MAPK1 | |
| SCHEMBL9318758 | 0.78 | KDM4E (0.60) | KDM4EALDH1A1ASPHKDM8P4HTM | |
| SCHEMBL935259 | 0.76 | KMO (0.51) | KDM4EALDH1A1SMN1; SMN2ASPHKDM8 | |
| SCHEMBL21633969 | 0.76 | KDM4E (0.63) | KDM4EALDH1A1SMN1; SMN2ASPHKDM8 | |
| SCHEMBL31513879 | 0.76 | KDM4E (0.47) | KDM4EALDH1A1SMN1; SMN2ASPHKDM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260078113-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2026-03-19 | — | — | US | disclosed |
| US-12516044-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| US-12516065-B2 | Tertiary alcohols as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| WO-2024220937-A2 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20240228498-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2024-07-11 | — | — | US | disclosed |
| CN-118063470-A | Condensed imidazole derivatives substituted with tertiary hydroxyl groups as PI 3K-gamma inhibitors | 因赛特公司 | 2024-05-24 | — | — | CN | disclosed |
| US-11926630-B2 | Tertiary alcohols as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2024-03-12 | — | — | US | disclosed |
| CN-111542526-B | Condensed imidazole derivatives substituted with tertiary hydroxyl groups as PI 3K-gamma inhibitors | 因赛特公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20220289732-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | NOVARTIS AG (CH) | 2022-09-15 | — | — | US | disclosed |
| US-20180273519-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-09-27 | — | — | US | disclosed |
| US-20170174671-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-06-22 | — | — | US | disclosed |
| WO-2017106634-A1 | N-PHENYL-PYRIDINE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION MODULATORS | INCYTE CORPORATION (US) | 2017-06-22 | — | — | WO | disclosed |
| EP-2588475-B1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2015-05-20 | — | — | EP | disclosed |
| US-8927582-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130203819-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-8440665-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2588475-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20120004267-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| WO-2012003387-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203819-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | AIFM1, MAP3K1, RIPK3 | KDM4E 2886/4885ALDH1A1 3284/4885SMN1; SMN2 1776/4885 |
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | KDM4E 810/4885ALDH1A1 3930/4885SMN1; SMN2 1897/4885 |
| US-20180273519-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | KDM4E 3674/4885ALDH1A1 247/4885SMN1; SMN2 4119/4885 |
| US-20240228498-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | PIK3R5, PIK3R1, PIK3CD | KDM4E 3139/4885ALDH1A1 333/4885SMN1; SMN2 1125/4885 |
| US-20220289732-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | WDR5, WDR77, WDR1 | KDM4E 127/4885ALDH1A1 2452/4885SMN1; SMN2 3786/4885 |
| US-20260078113-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | MSR1, NR3C1, CCR1 | KDM4E 4270/4885ALDH1A1 868/4885SMN1; SMN2 3526/4885 |
| US-20170174671-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | KDM4E 3674/4885ALDH1A1 247/4885SMN1; SMN2 4119/4885 |
| US-20120004267-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | AIFM1, MAP3K1, RIPK3 | KDM4E 2886/4885ALDH1A1 3284/4885SMN1; SMN2 1776/4885 |
| US-11926630-B2 | Tertiary alcohols as PI3K-γ inhibitors | PIK3R5, PIK3CG, PIK3CD | KDM4E 4006/4885ALDH1A1 155/4885SMN1; SMN2 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.